Navigating the advanced NSCLC patient pathway:
new markers and targets

ELCC 2016 Industry Satellite Symposium.
Thursday 14th April 2016, Geneva, Switzerland
Chaired by Martin Reck

  • Scientific Summary
    The faculty provided insight and guidance on the latest developments when treating NSCLC and how we can use our biological knowledge to improve both treatment pathways and outcomes in NSCLC. The report covers:

    • a presentation from Keith Kerr on trail markers in squamous NSCLC: signposts for clinical efficiency
    • a case study, presented by Johan Vansteenkiste: navigating the advanced NSCLC patient pathway
    • a panel discussion on patient management in the targeted age: finding the way through increased complexity – chaired by Martin Reck

    Click here to download the scientific summary
    English                                    Français

    elcc2016ReportThumb                              elcc2016Summary_FR-thumb



    • Trail markers in squamous NSCLC: signposts for clinical efficacy – Keith Kerr
    • Navigating the advanced NSCLC patient pathway: a case study – Johan Vansteenkiste
    • Patient management in the targeted age: finding the way through increased complexity – All
    • Closing remarks – Martin Reck
  • Following attendance at this symposium delegates are expected to:

    • Understand how best to use biomarkers to guide therapy for advanced squamous NSCLC
    • Understand and demonstrate knowledge on the latest treatment pathways for patients with advanced squamous NSCLC
    • Understand the emerging therapies for advanced squamous NSCLC and the new treatment paradigms they raise
  • Dear Colleagues,

    Welcome to Geneva and thank you for attending this satellite symposium ‘Navigating the advanced NSCLC patient pathway: new markers and targets’ at the European Lung Cancer conference, which we hope you will find engaging and informative.

    Geneva again provides an excellent host city for this conference bringing together a unique community of medical professionals to facilitate a personalised approach to the management of lung and other thoracic cancers, and the implementation of new discoveries, into clinical practice. This symposium will address the challenges of treating advanced NSCLC patients in an increasingly complex therapy landscape. The therapy landscape and, accordingly, the patient pathway through it, has greatly increased in complexity in recent years.

    During this session, the expert Faculty will guide us through this complexity by placing the latest developments in advanced NSCLC into the context of treatment. They will provide their insights into how we can use our biological knowledge not only to improve treatment pathways, but also to maximise treatment outcomes by understanding approaches. We hope that you find this symposium educational and that it will further your understanding of this evolving field, providing advice to facilitate decision making in your clinical practice.

    Accordingly, we aim to provide maximum interaction and discourse between Faculty and audience so that we may work together to optimise patient outcomes. We would be grateful if you would kindly provide your feedback by completing the evaluation form provided with this booklet.

    Yours faithfully,
    Martin Reck – Chair

  • Martin Reck
    (Symposium Chair)
    Grosshansdorf, Germany
    Professor Reck undertook his medical training at The University of Hamburg, Germany, from 1986 to 1993. He completed his doctorate at the General Hospital Wandsbek, Hamburg, in 1995 and received post-graduate training at the Hospital Grosshansdorf, Germany. In 2001 he was appointed as a specialist in internal medicine and in 2002 he was also appointed as a specialist in pulmonology. In 2008 he was awarded a post-doctoral lecturing qualification by the University of Schleswig-Holstein, Germany.

    Professor Reck has been a Principal Investigator (PI) or Co-PI in various clinical trials since 1993. His main interests are targeted therapies in non-small-cell lung cancer, new approaches in small-cell lung cancer and modern therapies in malignant pleural mesothelioma, as well as translational research related to predictive markers. He has been involved in several key trials investigating new treatment approaches in the treatment of advanced stage of disease such as, maintenance treatment or treatment with targeted therapies, as well as key biomarker trials.

    He is Head of the Department of Thoracic Oncology as well as Head of the Clinical Trial Department in the Department of Thoracic Oncology at the Lung Clinic Grosshansdorf. Furthermore he is PI in the German centre for lung research (DZL) in the area of lung cancer.
    Martin Reck is a member of: the German Working Group for Lung Cancer, the German Cancer Society, the German Society of Pulmonology, the International Association for the Study of Lung Cancer, the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO).

    Johan Vansteenkiste
    Leuven, Belgium
    Professor Vansteenkiste is Professor of Internal Medicine in the Faculty of Medicine at the Catholic University of Leuven, Belgium, and Head of Clinic in the Respiratory Oncology Unit and its Clinical Trial Unit at the Leuven University Hospital. He studied medicine at the University of Leuven before becoming a Board Certified Pulmonologist-Oncologist.
    He had additional training in respiratory oncology at the European School of Oncology in Milan, Italy, and in respiratory endoscopy at the Laser Centre in Marseille, France, before gaining his PhD at the University of Leuven in 1996.

    Professor Vansteenkiste is an active member of different international societies such as ESMO, IASLC, ASCO, and others. He was Secretary of the Thoracic Oncology Assembly of the ERS and a member of the ERS School Board in 2009-2012. He was a member of the Board of Directors of IASLC in 2009-2013. He is a member of the ESMO Lung Educational Group and Guidelines Group, and chaired the European Lung Cancer Conference in April 2015.
    He is the principal investigator or co-investigator in several clinical trials in the area of lung cancer.  He is Associate Editor at the Annals of Oncology, a member of the editorial board of several other journals, and author or co-author of more than 250 peer-reviewed papers and book chapters.

    Keith Kerr
    Aberdeen, UK
    Professor Kerr completed his BSc with first class honours in Pathology in 1978, followed by MB ChB in 1981 and post-graduate training in Pathology at Edinburgh University Medical School and the Royal Infirmary of Edinburgh. He obtained a MRCPath in 1988, FRCPath in 1998 and was elected Honorary FRCP(Ed) in 2006. He has been a Consultant Pathologist in Aberdeen since 1989.
    Professor Kerr has been a member of the IASLC for 16 years. He was elected to the IASLC Board of Directors for four years, 2013-2017, and is also Associate Editor for the Journal of Thoracic Oncology.

    Professor Kerr is also a member of the International Mesothelioma Panel, and served as Pathology Chair for the The European Organisation for Research and Treatment of Cancer (EORTC) lung cancer group from 2006-2014. He is Pathology Chair for the ETOP Lungscape group and was a member of the panel for the 2004 and 2015 WHO lung cancer classifications. He serves on the International Pulmonary Pathology Society council and is a British Thoracic Society member.
    He is currently involved in the revision of the BTS Mesothelioma guidelines and is a panel member for the revision of the The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) guidelines for molecular pathology testing in lung cancer. He is a lead author of the ESMO Consensus Guidelines on pathology and molecular biomarkers for non-small-cell lung cancer.

    Throughout his career, he has worked in diagnostic histopathology with a special interest in thoracic pathology. He has had a career-long interest in lung cancer and has research interests in pulmonary pre-neoplasia and carcinogenesis, lung tumour diagnosis and classification, and in the identification of predictors of therapy response.